EUCTR2017-003238-96-DK进行中（未招募）1 期
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED MAINTENANCE STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 2) - LUCENT 2
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,044
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Have completed Study AMAN, with at least 1 study drug administration, without early termination of study drug, and underwent a Visit 5 (Week 12) endoscopy.
- •2. Are willing and able to complete the scheduled study assessments, including endoscopy and daily diary entry.
- •3. If female, must meet the contraception requirements.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 940
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 104
排除标准
- •1. Participants diagnosed with Crohn’s disease or inflammatory bowel disease-unclassified (indeterminate colitis) during the induction study AMAN.
- •2. Participants with a bowel resection or other surgery for the treatment of UC during the previous induction study AMAN, or are likely to require surgery for the treatment of UC during study AMBG.
- •3. Participants with evidence of colonic dysplasia or have been diagnosed with cancer of the gastrointestinal tract during study AMAN.
- •4. Participants diagnosed with clinically important infection including, but not limited to, hepatitis B, hepatitis C, HIV/AIDS, and active tuberculosis (TB) during the induction study AMAN.
- •5. Participants who initiate a new prohibited medication during the induction study AMAN.
- •6. Participants with certain laboratory abnormalities prior to start of AMBG that would require permanent discontinuation from study drug.
研究者
相似试验
招募中
1 期
A Phase 3 Study of Obexelimab in Patients with IgG4-Related DiseaseIgG4-Related DiseaseMedDRA version: 21.0Level: LLTClassification code: 10071581Term: IgG4 related sclerosing disease Class: 10028395CTIS2022-500718-24-00Zenas Biopharma (USA) LLC225
进行中（未招募）
1 期
A study to evaluate the efficacy and safety ofbimekizumab in subjects with activenonradiographic axial spondyloarthritisonradiographic axial spondyloarthritisMedDRA version: 20.0Level: LLTClassification code 10076297Term: Non-radiographic axial spondyloarthritisSystem Organ Class: 100000004859EUCTR2017-003064-13-BECB Biopharma SR240
进行中（未招募）
1 期
A MAINTENANCE STUDY OF THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN ULCERATIVE COLITISModerately to Severely Active Ulcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2017-003238-96-NLEli Lilly and Company1,044
已完成
不适用
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATOR-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS TO ORAL DELAFLOXACIN IN ADULT SUBJECTS WITH COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA-J159 Bacterial pneumonia, unspecifiedBacterial pneumonia, unspecifiedJ159PER-016-17Melinta Therapeutics, Inc.,4
进行中（未招募）
1 期
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ATOGEPANT FOR THE PREVENTION OF CHRONIC MIGRAINE (PROGRESS)EUCTR2018-004337-32-GBAllergan Limited750